Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.

被引：13

作者：

Locke, Frederick Lundry

Ghobadi, Armin

Lekakis, Lazaros J.

Miklos, David Bernard

Jacobson, Caron A.

Jacobsen, Eric D.

Braunschweig, Ira

Oluwole, Olalekan O.

Siddiqi, Tanya

Lin, Yi

Reagan, Patrick Michael

Farooq, Umar

Deol, Abhinav

Bot, Adrian

Rossi, John M.

Jiang, Yizhou

Xue, Allen

Go, William Y.

Neelapu, Sattva Swarup

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Washington Univ, Sch Med, St Louis, MO USA

[3] Univ Miami Hlth Syst, Sylvester Comprehens Care Ctr, Miami, FL USA

[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA

[7] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[8] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[9] Mayo Clin, Rochester, MN USA

[10] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

[11] Univ Iowa, Iowa City, IA USA

[12] Wayne State Univ, Karmanos Canc Ctr, Detroit, MI USA

[13] Kite, Santa Monica, CA USA

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.3039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3039

引用

页数：2

共 50 条

[41] Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 12 - 14
[42] ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B-cell lymphoma (LBCL).
Neelapu, Sattva Swarup
Chavez, Julio C.
Lin, Yi
Munoz, Javier
Ujjani, Chaitra Shankar
Riedell, Peter
De Vos, Sven
Oluwole, Olalekan O.
Kekre, Natasha
Yang, Yin
Goyal, Lovely
Backhouse, Kate
Milletti, Francesca
Kawashima, Jun
Herrera, Alex Francisco
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[43] Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)
Neelapu, Sattva S.
Dickinson, Michael
Ulrickson, Matthew L.
Oluwole, Olalekan O.
Herrera, Alex F.
Thieblemont, Catherine
Ujjani, Chaitra S.
Lin, Yi
Riedell, Peter A.
Kekre, Natasha
de Vos, Sven
Yang, Yin
Milletti, Francesca
Goyal, Lovely
Kawashima, Jun
Chavez, Julio C.
BLOOD, 2020, 136
[44] Efficacy, safety, and covariates of outcomes with axicabtagene ciloleucel (axi-cel; KTE-C19) from ZUMA-1, a pivotal trial in patients with refractory, aggressive non-Hodgkin lymphoma (NHL)
Lin, Y.
Locke, L.
Neelapu, S. S.
Bartlett, N. L.
Lekakis, L. J.
Miklos, D.
Jacobson, C. A.
Braunschweig, I.
Oluwole, O.
Siddiqi, T.
Timmerman, J.
Reagan, P. M.
Bot, A.
Rossi, J.
Navale, L.
Jiang, Y.
Aycock, J. S.
Elias, M.
Wiezorek, J.
Go, W. Y.
HUMAN GENE THERAPY, 2017, 28 (12) : A5 - A5
[45] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
Oluwole, Olalekan O.
Forcade, Edouard
Munoz, Javier
de Guibert, Sophie
Vose, Julie M.
Bartlett, Nancy L.
Lin, Yi
Deol, Abhinav
McSweeney, Peter A.
Goy, Andre H.
Kersten, Marie Jose
Jacobson, Caron A.
Farooq, Umar
Minnema, Monique C.
Thieblemont, Catherine
Timmerman, John
Stiff, Patrick
Avivi, Irit
Tzachanis, Dimitrios
Zheng, Yan
Vardhanabhuti, Saran
Nater, Jenny
Shen, Rhine R.
Miao, Harry
Kim, Jenny
van Meerten, Tom
BLOOD, 2022, 140 : 10399 - 10401
[46] Preliminary results of earlier steroid use with axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory large B cell lymphoma
Topp, M. S.
van Meerten, T.
Wermke, M.
Lugtenburg, P. J.
Minnema, M. C.
Song, K. W.
Thieblemont, C.
Jiang, Y.
Plaks, V
Kerber, A.
Kersten, M. J.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 65 - 66
[47] ZUMA-1 Pivotal Phase 2 Trial of Axicabtagene Ciloleucel (axi-cel, KTE-C19; Anti-CD19 CAR T Cells) in Patients (pts) with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Neelapu, Sattva S.
Locke, Frederick L.
Ghobadi, Armin
Lekakis, Lazaros J.
Miklos, David
Jacobson, Caron A.
Braunschweig, Ira
Oluwole, Olalekan
Siddiqi, Tanya
Lin, Yi
Timmerman, John
Stiff, Patrick J.
Flinn, Iann
Goy, Andre
Smith, Mitchell
Deol, Abhinav
Farooq, Umar
McSweeeny, Peter
Munoz, Javier
Avivi, Irit
Reagan, Patrick
Bot, Adrian
Rossi, John
Navale, Lynn
Jiang, Yizhou
Aycock, Jeff
Elias, Meg
Wiezorek, Jeff
Go, William Y.
MOLECULAR THERAPY, 2017, 25 (05) : 333 - 333
[48] Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).
Locke, Frederick Lundry
Neelapu, Sattva Swarup
Bartlett, Nancy L.
Lekakis, Lazaros J.
Miklos, David Bernard
Jacobson, Caron Alyce
Braunschweig, Ira
Oluwole, Olalekan
Siddiqi, Tanya
Lin, Yi
Timmerman, John
Reagan, Patrick Michael
Bot, Adrian
Rossi, John
Navale, Lynn
Jiang, Yizhou
Aycock, Jeff
Elias, Meg
Wiezorek, Jeffrey S.
Go, William Y.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[49] Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.
Strati, Paolo
Leslie, Lori Ann
Shiraz, Parveen
Budde, L. Elizabeth
Oluwole, Olalekan O.
Ulrickson, Matthew
Ramakrishnan, Aravind
Sun, Jennifer
Shen, Rhine
Kanska, Justyna
McCroskery, Peter
Dong, Jinghui
Schupp, Marco Andreas
Xu, Hairong
Patel, Krish
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[50] Long-Term Follow-Up of ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients With Refractory Aggressive Non-Hodgkin Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 7 - 9

← 1 2 3 4 5 →